Glycochemistry and Glycobiology Lab, Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, PR China; University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, PR China.
Glycochemistry and Glycobiology Lab, Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, PR China; University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, PR China.
Carbohydr Polym. 2018 Sep 1;195:643-651. doi: 10.1016/j.carbpol.2018.05.022. Epub 2018 May 7.
The β amyloid (Aβ) induced neurodegeneration is believed to be one of pathological mechanisms of Alzheimer's disease (AD). The inhibition of Aβ production or aggregation is one of the promising therapeutic strategies for anti-AD drug discovery. Here, a homogeneous neutral polysaccharide designated LBP1A1-1 with an average molecular weight of 45.0 kDa was purified from fruits of Lycium barbarum L. Its structure was characterized to possess a backbone of 1, 3-linked β-Galp, 1, 6-linked β-Galp, 1, 4-linked α-Glcp with branches substituted at C-3 position of 1, 6-linked β-Galp or C-6 position of 1, 3-linked β-Galp. The branches contained terminal (T)-linked β-Galp, T-linked α-Araf, T-linked β-Araf, 1, 5-linked α-Araf and T-linked β-Rhap. The in vitro experiments revealed that LBP1A1-1 could inhibit Aβ production and impede Aβ aggregation in a dose-dependent-manner without cytotoxicity. These results suggested that LBP1A1-1 might have the multiple potential for the treatment of AD.
β淀粉样蛋白（Aβ）诱导的神经退行性变被认为是阿尔茨海默病（AD）的病理机制之一。抑制 Aβ 的产生或聚集是抗 AD 药物发现的有前途的治疗策略之一。在这里，从枸杞的果实中纯化出一种均相中性多糖，命名为 LBP1A1-1，其平均分子量为 45.0 kDa。其结构特征为具有 1,3-连接的β-Galp、1,6-连接的β-Galp、1,4-连接的α-Glcp 的主链，分支取代 1,6-连接的β-Galp 或 1,3-连接的β-Galp 的 C-6 位置。支链含有末端（T）连接的β-Galp、T 连接的α-Araf、T 连接的β-Araf、1,5-连接的α-Araf 和 T 连接的β-Rhap。体外实验表明，LBP1A1-1 可在无细胞毒性的情况下，以剂量依赖的方式抑制 Aβ 的产生和阻止 Aβ 的聚集。这些结果表明，LBP1A1-1 可能具有治疗 AD 的多种潜力。
